AURION BIOTECH

Greg Kunst, CEO
David Rostov, CFO

Q1 2022

Forward-looking Statements

Disclaimer

This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact could be deemed forward-looking, including, but not limited to, any projections of financial information; any statements about historical results that may suggest trends for our business; any statements of the plans, strategies, and objectives of management for future operations; any statements of expectation of belief regarding future events, potential markets or market size, technology developments, or enforceability of our intellectual property rights; any statements regarding our ability to successfully launch and commercialize new product offerings including Cornea Cell Therapy (CCT) and other products or potential products and the timing thereof; and any statements of assumptions underlying any of the items mentioned.

These statements are based on estimates and information available to us at the time of this presentation and are not guarantees of future performance. Actual results could differ materially from our current expectations as a result of many factors, including, but not limited to, quarterly fluctuations in our business; market acceptance of our offerings; the effects of competition and technological advances on our ability to successfully commercialize our offerings; the regulatory regime for our offerings; and any adverse changes in our strategic relationships, including with licensors of our technologies and manufacturers and distributors of our offerings; and adverse conditions in the general domestic and global economic markets. We assume no obligation and do not intend to update these forward-looking statements or to conform these statements to actual results or to changes in our expectations.

AURION BIOTECH

Cell Therapy to Cure Corneal Endothelial Blindness

Corneal Endothelial Disease Affects 16 Million People in US, EU and Japan



- We manufacture corneal endothelial cells *in vitro*
- Cells from one donor can produce 100+ cell therapy treatments



- Our cells are injected into blind patient's eye
- Within days, patient's vision is restored

AURION BIOTECH

Investment Highlights

Corneal Endothelial Disease: $4.75B Market	• 16M people US/EU/Japan, but few are treated (<70,000 / year) • Barriers: limited organ supply, complex surgery, economic disincentives
Clinical Validation: 100+ Patients Treated	• Demonstrated efficacy, safety and durability (incl. 5-year follow-up data) • Injectable procedure: potential to expand treatment paradigm
Well-Defined Regulatory Pathway	• Japan: NDA submission 2H 2022 • US: IND submission 2H 2022
Leverageable Platform	• First indication: severe corneal endothelial disease • Additional opportunities: glaucoma, ocular surface disease, AMD
Deep Industry Experience	• Management: Novartis, Glaukos, Alcon, Biogen, Bausch & Lomb, AcuFocus, CorneaGen, Dendreon • Investors: Flying-L-Partners, Falcon Vision (KKR), Petrichor, Visionary Ventures

AURION BIOTECH

Aurion Biotech At a Glance



AURION BIOTECH

Corneal Endothelial Cells – Essential to Vision



What They Are / Why They Matter

- Single layer of cells covering cornea's posterior surface
- **"Pump-and-barrier" mechanism**
  - –Regulate hydration: maintain transparency & cornea health
- **Avascular & immuno-privileged**
  - –Tolerate antigens without eliciting inflammatory immune response
- Once diseased, cells **do not repair / regenerate**
  - –Damage can cause blindness

AURION BIOTECH

Patient Perspective: Corneal Blindness

Cloudy Cornea



Glare & Halos

Blurred Vision



Photos source: Kinoshita, S. et al, Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy, NEJM 2018

AURION BIOTECH

Cell Therapy Restores Patients' Vision

Clear Cornea



Reduced Glare



Clear Vision



Photos source: Kinoshita, S. et al, Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy, NEJM 2018

AURION BIOTECH

Large Market Opportunity, But Few Are Treated

4% of Population Age 40+ have Corneal Endothelial Disease[1]

Total Prevalence

– 16 Million People[1]

Annual Incidence

– 500,000 People[2]

$4.75 Billion TAM

– 475k eyes x $10k per procedure[3]

Endothelial Keratoplasties (DMEK / DSAEK): Annual Treatments[2]



[1] Source: NIH; JAMA: Global Survey of Corneal Transplantation & Eye Banking

[2] EBAA 2020 Annual Report; company analysis

[3] Syneos study: $20k - $25k payor reimbursement per procedure

AURION BIOTECH

Hurdles with Standard of Care (DMEK / DSAEK)

- Limited donor cornea supply
  - 1 for every 70 diseased eyes[1]
- Challenging, complex, invasive surgery
  - Few skilled surgeons
  - Regraft and re-bubbling problems
- Unfavorable economics
  - Procedure times
  - Reimbursement

[1] Source: JAMA Survey. 2016

AURION BIOTECH

Aurion Biotech Cell Therapy: Key Success Factors

Solves Unmet Need for Donor Corneal Tissue	• 1 donor → manufacture cells for 100+ treatments
Simple Injection	• Minimally invasive, rapid (~10 minutes) • Patient-friendly recovery
Available & Broadly Accessible	• Straightforward for ophthalmologists to learn
Favorable Economics	• Potential premium to current standard of care • Medicare Part-B injectable

AURION BIOTECH

The Potential for Our Cell Therapy



AURION BIOTECH

Corneal Endothelial Cell Therapy Procedure – How it Works



- Diseased endothelium removed from patient



- Cells in suspension injected into patient's anterior chamber
- Cells quickly self-align

- Patient recovers in prone position

AURION BIOTECH

Clinical Data: 100 Patients Treated to Date

Clinical Research in Japan: Long-Term Safety & Efficacy

First 11 Patients; Ages 49-82 at Study Launch

The NEW ENGLAND JOURNAL of MEDICINE

Ophthalmology

Exploratory Endpoints	Baseline (pre-procedure)	6 Months	2 Years	5 Years	Healthy Range[1]
Mean Corneal Thickness (µm)	**743**	**549**	**552**	**555**	**540 - 555**
Mean Visual Acuity (Snellen)	**20/220**	**20/33**	**20/23**	**20/30**	**20/20 - 20/40**
Safety / Tolerability	n/a	No serious adverse events	No serious adverse events	No serious adverse events	n/a

[1]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810328/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545036/#!po=8.33333

AURION BIOTECH

Versatile Procedure: IOTA Trial (El Salvador)

Sample of patients treated in November 2020



AURION BIOTECH

US Clinical Development Plan

Clinical Development Status

- Submit J-NDA to Japan PMDA
  - 2H 2022
- Submit IND to US FDA
  - 2H 2022

AURION BIOTECH

Manufacturing / IP

Endothelial Cell Therapy Manufacture – How it Works

Proprietary cell replication technology: cells from single donor can treat 100+ eyes

1



- Donor cornea is harvested
- Corneal endothelial cells (CECs) are isolated *in vitro*

2



- Donor CECs are introduced to proprietary culture and propagation begins

3



- CECs are grouped into smaller volumes and moved to flasks for more cell production
- Process repeats for multiple passages

AURION BIOTECH

Management Team

Greg Kunst
Chief Executive Officer

- Glaukos
  Alcon (Novartis)
  Kinetic Concepts (Acelity)
- Herbert Eye Institute, UCI

David Rostov
Chief Financial Officer

- Donuts, Inc.
- Avalara
- Lighthouse Global
- InfoSpace
- drugstore.com

Arnaud Lacoste, MBA, PhD
Chief Scientific Officer

- Novartis (group head, cell & gene therapy)
- Rockefeller University
- Inseron

Daniela Drago, MS, PhD
Chief Regulatory Officer

- Biogen
- NDA Partners
- Geo. Washington Univ. School of Medicine
- Bausch & Lomb
- Reckitt Benckiser
- Hoffman La Roche

Eris Jordan, OD
VP Clinical Dev't

- Bascom Palmer Eye Institute
- CorneaGen
- AcuFocus
- Bausch & Lomb

Tim Largen
VP Manufacturing

- Lykan Bioservices
- Dendreon
- Caladrius
- Argos Therapeutics
- Molecular Insight Pharma
- NeoRx

Judith McGarry
VP Marketing

- Adaptive Biotechnologies
- Hyperion Therapeutics
- CoTherix

Medical Advisory Board

Edward Holland, MD
Advisory Board Chair

Cincinnati Eye Institute

Shigeru Kinoshita, MD, PhD
Cell Therapy Inventor

Kyoto Prefecture Univ. of Medicine

Richard Lindstrom, MD

MN Eye Consultants

Elizabeth Yeu, MD

Virginia Eye Consultants

Investment Highlights

Corneal Endothelial Disease: $4.75B Market	• 16M people US/EU/Japan, but few are treated • Barriers: limited organ supply, complex surgery
Clinical Validation: 100+ Patients Treated	• Demonstrated efficacy, safety and durability (in • Injectable procedure: potential to expand treat
Well-Defined Regulatory Pathway	• Japan: NDA submission 2H 2022 • US: IND submission 2H 2022
Leverageable	• First indication: severe corneal endothelial dise


www.aur

Browse the best pitch deck examples.

Brought to you by bestpitchdeck.com — the world's largest library of pitch decks: hundreds of winning presentations from leading startups, updated every week.